# An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

> **NCT00524524** · PHASE1 · COMPLETED · sponsor: **ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)** · enrollment: 9 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** ARQ 501

## Key facts

- **NCT ID:** NCT00524524
- **Lead sponsor:** ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2011-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00524524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00524524, "An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00524524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*